New study tracks drug safety for pregnant women with nerve disorders

NCT ID NCT06299748

First seen Nov 05, 2025 · Last updated May 10, 2026 · Updated 30 times

Summary

This study follows pregnant or breastfeeding women who have taken efgartigimod for myasthenia gravis or CIDP. Researchers will monitor mothers, fetuses, and infants for any health issues, including birth defects. The goal is to gather safety data, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    RECRUITING

    Roma, 00168, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, 08035, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Klinikum der Ruhr-Universität Bochum St. Josef Hospital Neurologische Interdisziplinäre Infusionsambulanz + MS Studienambulanz (Haus E Ebene1)

    RECRUITING

    Bochum, 44791, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • United BioSource LLC

    RECRUITING

    Morgantown, West Virginia, 26508, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.